Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Recursion Pharmaceuticals's total assets was $1.21B at Jun 30, 2026. For fiscal 2025 it was $1.47B, up 1.8% from the year before. The highest annual figure on record is $1.47B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | +1.8% |
| FY2024 | Dec 31, 2024 | $1.45B | +121.6% |
| FY2023 | Dec 31, 2023 | $653.70M | -6.8% |
| FY2022 | Dec 31, 2022 | $701.29M | +14.9% |
| FY2021 | Dec 31, 2021 | $610.35M | +104.4% |
| FY2020 | Dec 31, 2020 | $298.59M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.21B | -6.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.34B | +2.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.47B | +1.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.40B | +92.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.30B | +67.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.31B | +134.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.45B | +121.6% |
| Q3 FY2024 | Sep 30, 2024 | $726.50M | +15.2% |
| Q2 FY2024 | Jun 30, 2024 | $775.86M | +16.4% |
| Q1 FY2024 | Mar 31, 2024 | $557.85M | -11.1% |
| Q4 FY2023 | Dec 31, 2023 | $653.70M | -6.8% |
| Q3 FY2023 | Sep 30, 2023 | $630.83M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $666.70M | -0.9% |
| Q1 FY2023 | Mar 31, 2023 | $627.37M | -14.6% |
| Q4 FY2022 | Dec 31, 2022 | $701.29M | +14.9% |
| Q3 FY2022 | Sep 30, 2022 | $611.53M | -7.1% |
| Q2 FY2022 | Jun 30, 2022 | $672.52M | -3.7% |
| Q1 FY2022 | Mar 31, 2022 | $734.32M | +170.0% |
| Q4 FY2021 | Dec 31, 2021 | $610.35M | +104.4% |
| Q3 FY2021 | Sep 30, 2021 | $658.61M | – |
| Q2 FY2021 | Jun 30, 2021 | $698.59M | – |
| Q1 FY2021 | Mar 31, 2021 | $271.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $298.59M | – |
See a number that looks wrong?